Results 91 to 100 of about 4,104 (188)

Pasireotide prevents nuclear factor of activated T cells nuclear translocation and acts as a protective agent in aminoglycoside‐induced auditory hair cell loss [PDF]

, 2016
Daniel Bodmer, Adrijana Perkovic, Marijana Sekulic‐Jablanovic, Matthew B. Wright, Vesna Petkovic   +4 more
openalex   +1 more source

Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study [PDF]

, 2019
Sabrina Chiloiro, Chiara Bima, Tommaso Tartaglione, Antonella Giampietro, Marco Gessi, Liverana Lauretti, Carmelo Anile, Cesare Colosimo, Guido Rindi, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi   +11 more
openalex   +1 more source

Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial [PDF]

, 2008
Marco Boscaro, W.H. Ludlam, Brew Atkinson, J. E. Glusman, Stephan Petersenn, Martín Reincke, Peter J. Snyder, Antoine Tabarin, Beverly M. K. Biller, James W. Findling, Шломо Мелмед, C. H. Darby, Ke Hu, Y. Wang, Pamela U. Freda, Ashley Grossman, L A Frohman, Jérôme Bertherat   +17 more
openalex   +1 more source

Pasireotide treatment in giant prolactinoma resistant to dopamine agonists.

Endokrynologia Polska
Not required for Clinical Vignette.
M. Komisarz-Calik, G. Zieliński, K. Ciszek, A. Bogusławska, A. Hubalewska-Dydejczyk, Aleksandra Gilis-Januszewska   +5 more
semanticscholar   +1 more source

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

ClinicoEconomics and Outcomes Research, 2019
Laura Sánchez-Cenizo,1 Javier Aller,2 José Manuel Martínez-Sesmero,3 Nuria Mir,1 Carmen Peral,1 Darío Rubio-Rodríguez,4 Carlos Rubio-Terrés41Medical Department, Pfizer, S.L.U, Madrid, Spain; 2Endocronology ...
Sánchez-Cenizo L, Aller J, Martínez-Sesmero JM, Mir N, Peral C, Rubio-Rodríguez D, Rubio-Terrés C   +6 more
doaj  

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study [PDF]

, 2016
Maria Fleseriu, Elisha S. Rusch, Eliza B. Geer   +2 more
openalex   +1 more source

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease

, 2021
Márcio Carlos Machado, Valter Ângelo Sperling Cescato, Maria Candida Barisson Villares Fragoso, Marcello D. Bronstein   +3 more
openalex   +1 more source

Management of Acromegaly With Pasireotide LAR: A Case Study of Sustained Biochemical Control and Tumor Volume Reduction Without Worsening of Glycemia

, 2015
Kevin C.J. Yuen
openalex   +1 more source

A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome [PDF]

, 2016
Laura Trementino, Grazia Michetti, Alessia Angeletti, Giorgia Marcelli, Carolina Concettoni, C. Cardinaletti, Barbara Polenta, Marco Boscaro, Giorgio Arnaldi   +8 more
openalex   +1 more source

SAT-305 Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide [PDF]

, 2020
Pooja Dasgupta, Stefan Schulz
openalex   +1 more source